MGMT and glioblastoma: Although a subset of patients containing methylated O6-methylguanine-DNA methyltransferase (MGMT) promotor show a better response to treatment with a median survival of 22 months [3], there is urgent need for better second-line therapies for recurrent GBM that responds poorly to first-line therapies [4], [5].